Akademik Veri Yönetim Sistemi
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, cilt.11, sa.1, ss.44-50, 2010 (SCI-Expanded)
Objective: The aim of the study was to compare efficacy and tolerability of OROS-methylphenidate HCL (OROS-MPH) with immediate-release methylphenidate (IR-MPH) in Turkish children with attention-deficit/hyperactivity disorder (ADHD). Methods: This study was designed as an open label, prospective, for an 8-week period. A total of 83 subjects, between the ages of 7 and 14 with ADHD, were included in this study. The dosages of OROS-MPH and IR-MPH were adjusted by the investigators based on symptoms and adverse events assessments performed (OROS-MPH doses: 18-36 mg/day-once daily, IR-MPH doses: 10-20 mg/day-divided dose). The efficacy and adverse effects of the drugs were assessed due to Turgay DSM-IV-Based Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S), Clinical Global Impression-Global improvement Scale (CGI-GI), and Methylphenidate Side Effects Rating Form (MSERF). Results: Both OROS-MPH and IR-MPH showed definitive improvement of severity symptoms of ADHD (p<0.05). No significant differences were found between two groups at 8th week in mean scores of T-DSM-IV and CGI-GI. Weight loss was found to be related with the dose increase according to parents' reports on adverse effects of OROS-MPH. Conclusion: OROS-MPH was found to be as effective as IR-MPH in the treatment of behavioral symptoms in Turkish children with ADHD. These results demonstrated that both drugs were effective and well tolerated in the treatment of Turkish children with ADHD. (Anatolian Journal of Psychiatry 2010; 11:44-50)